

IMARX THERAPEUTICS INC

Form 8-K

September 20, 2007

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
September 10, 2007  
Date of Report (Date of earliest event reported)  
IMARX THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**001-33043**

**86-0974730**

**(State or other jurisdiction of  
incorporation)**

**(Commission File Number)**

**(I.R.S. Employer  
Identification Number)**

**1635 East 18<sup>th</sup> Street  
Tucson, AZ 85719-6803  
(Address of principal executive offices)  
(520) 770-1259**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events.

Item 9.01 Financial Statements and Exhibits.

SIGNATURES

EX-99.1

---

**Table of Contents**

**Item 8.01 Other Events.**

On September 20, 2007, ImaRx Therapeutics issued the press release attached to this report as Exhibit 99.1. The content of the press release is incorporated herein by this reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release issued by ImaRx Therapeutics, Inc. on September 20, 2007.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 20, 2007

**IMARX THERAPEUTICS, INC.**

By:

/s/ Kevin Ontiveros  
Kevin Ontiveros,  
Vice President, Legal Affairs,  
General Counsel and Secretary

3